Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Strategic Divestitures and Operating Model Realignment
BAX logo

Baxter Sells Kidney Care for $3.8B, Reduces Debt by $3.8B Amid 5% Sales Growth

BAX10-QFiling Date: 11/4/2025
Baxter International Inc.
Description

What this story covers

Baxter's Q3 2025 10-Q details the $3.8B Kidney Care sale, netting $3.3B for debt reduction, and a new three-segment model. Sales rose 5% to $2.8B quarterly, but margins fell due to recalls and supply issues. Liquidity is strong with $1.7B cash and lower leverage at 2.5x EBITDA, navigating challenges for focused growth.

Story snapshot

CompanyBaxter International Inc.
TickerBAX
VariantStandard detailed
Duration9:55
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001628280-25-048897

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in